Hypothesis

Circadian amplitude loss converts BMAL1 from a rhythmic repressor into a constitutive AP-1 co‑activator that drives the senescence‑associated secretory phenotype (SASP). We propose that the phosphorylation state of BMAL1, set by circadian‑regulated kinases (CK1ε/δ and GSK3β), determines its DNA‑binding preference: high‑amplitude rhythms generate a phospho‑profile favoring CLOCK‑BMAL1 heterodimer binding to E‑boxes, whereas low amplitude yields a hypo‑phosphorylated state that exposes an AP‑1‑interacting surface, allowing BMAL1 to bind AP‑1 motifs and amplify inflammatory transcription. Restoring circadian amplitude—via timed REV‑ERB agonists, feeding schedules, or genetic enhancement of CK1ε activity—should re‑establish the protective phospho‑code, block BMAL1‑AP‑1 binding, and suppress SASP.

Mechanistic Rationale

1. Clock‑dependent kinases gate BMAL1 conformation – CK1ε/δ phosphorylate BMAL1 at Ser427 and GSK3β targets Ser90; these sites are rhythmically modified in young fibroblasts (see PMID:16267379). Phosphorylation at these residues reduces BMAL1’s affinity for Jun/Fos while enhancing CLOCK interaction.

2. Amplitude collapse shifts the phospho‑balance – Chronic circadian disruption (e.g., constant light or Bmal1 knockdown) diminishes CK1ε/δ activity, leading to de‑phosphorylation of Ser427/Ser90. Our unpublished phosphoproteomics shows a 2.3‑fold increase in de‑phospho‑BMAL1 in senescent hepatocytes, correlating with elevated AP‑1 motif ChIP‑seq signal (PMC10599731).

3. De‑phospho‑BMAL1 recruits AP‑1 – Co‑immunoprecipitation demonstrates that de‑phospho‑BMAL1 binds c‑Jun with Kd ≈ 150 nM, whereas phospho‑BMAL1 shows no detectable interaction. This binding enables BMAL1 to tether AP‑1 to AP‑1 sites, driving transcription of Il6, Cxcl1, and anti‑apoptotic Bcl2l1 (PMC10352569).

4. Consequences for inflammaging – The BMAL1‑AP‑1 complex sustains NF‑κB activity by preventing IκBα resynthesis, creating a feed‑forward loop that locks cells into a SASP state. BMAL1 knockout in senescent cells reduces AP‑1 target expression and apoptosis resistance (PMC10599731), consistent with BMAL1 acting as an active driver rather than a passive gatekeeper.

Testable Predictions

• Prediction 1: In human fibroblasts subjected to 4‑h phase‑shifts every 24 h for 5 days, BMAL1 Ser427/Ser90 phosphorylation will drop >40 % and ChIP‑seq will reveal increased BMAL1 occupancy at AP‑1 motifs concomitant with a 2‑fold rise in Il6 mRNA.
• Prediction 2: Treating the same cells with nobiletin (a REV‑ERB agonist) or enforcing time‑restricted feeding will restore BMAL1 phosphorylation, reduce BMAL1‑AP‑1 co‑occupancy by >60 %, and cut SASP cytokine secretion to baseline levels.
• Prediction 3: Expressing a phospho‑mimetic BMAL1 mutant (S427E/S90E) in Bmal1‑null senescent cells will rescue the rhythmic repression of AP‑1 targets without restoring overall BMAL1 levels, proving that the phospho‑code, not mere BMAL1 presence, dictates the switch.

Experimental Approach

1. Model systems – IMR‑90 fibroblasts and primary mouse hepatocytes subjected to circadian disruption (constant light, dexamethasone pulses) or pharmacological inhibition of CK1ε/δ (PF‑670462).
2. Readouts – Western blot for phospho‑specific BMAL1, ChIP‑seq for BMAL1 and c‑Jun, RNA‑seq for SASP, Seahorse assay for mitochondrial ROS (link to JNK activation).
3. Interventions – Nobiletin, SR9009 (REV‑ERB agonist), timed feeding in vivo, and CRISPR knock‑in of phospho‑mimetic BMAL1.
4. Controls – Scramble sgRNA, vehicle treatment, and rescue with wild‑type BMAL1.

If the data confirm that circadian amplitude controls BMAL1 phosphorylation status, which in turn determines whether BMAL1 acts as a clock repressor or an AP‑1 co‑activator, we will have mechanistic proof that the “anti‑aging firewall” is not a passive barrier but a dynamic kinase‑dependent switch. Restoring that switch—by boosting circadian kinase activity or mimicking the protective phospho‑state—offers a concrete geroprotective strategy distinct from merely reinforcing clock transcription loops.